Literature DB >> 29872557

The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells.

Xinxin Li1,2, Wenjuan Dong1, Ansel P Nalin1, Yufeng Wang1, Pan Pan3, Bo Xu1, Yibo Zhang1, Steven Tun1, Jianying Zhang4, Li-Shu Wang3, Xiaoming He5, Michael A Caligiuri1,6,7, Jianhua Yu1,6,7.   

Abstract

Natural products comprise an important class of biologically active molecules. Many of these compounds derived from natural sources exhibit specific physiologic or biochemical effects. An example of a natural product is chitosan, which is enriched in the shells of certain seafood that are frequently consumed worldwide. Like other natural products, chitosan has the potential for applications in clinical medicine and perhaps in cancer therapy. Toward this end, the immunomodulatory or anti-cancer properties of chitosan have yet to be reported. In this study, we discovered that chitosan enhanced the anti-tumor activity of natural killer (NK) cells by activating dendritic cells (DCs). In the presence of DCs, chitosan augmented IFN-γ production by human NK cells. Mechanistically, chitosan activated DCs to express pro-inflammatory cytokines such as interleukin (IL)-12 and IL-15, which in turn activated the STAT4 and NF-κB signaling pathways, respectively, in NK cells. Moreover, chitosan promoted NK cell survival, and also enhanced NK cell cytotoxicity against leukemia cells. Finally, a related in vivo study demonstrated that chitosan activated NK cells against B16F10 tumor cells in an immunocompetent syngeneic murine melanoma model. This effect was accompanied by in vivo upregulation of IL-12 and IL-15 in DCs, as well as increased IFN-γ production and cytolytic degranulation in NK cells. Collectively, our results demonstrate that chitosan activates DCs leading to enhanced capacity for immune surveillance by NK cells. We believe that our study has future clinical applications for chitosan in the prevention or treatment of cancer and infectious diseases.

Entities:  

Keywords:  Chitosan; IFN-γ; anti-tumor; dendritic cells; natural killer cells

Year:  2018        PMID: 29872557      PMCID: PMC5980345          DOI: 10.1080/2162402X.2018.1431085

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  51 in total

1.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells.

Authors:  A Langenkamp; M Messi; A Lanzavecchia; F Sallusto
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

Review 2.  An intermittent approach for cancer chemoprevention.

Authors:  Xiangwei Wu; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

Review 3.  Targeting the epigenome with bioactive food components for cancer prevention.

Authors:  Thomas Prates Ong; Fernando Salvador Moreno; Sharon Ann Ross
Journal:  J Nutrigenet Nutrigenomics       Date:  2012-02-22

Review 4.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

Review 5.  The role of aspirin in cancer prevention.

Authors:  Michael J Thun; Eric J Jacobs; Carlo Patrono
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

6.  The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling.

Authors:  Youcai Deng; Jianhong Chu; Yulin Ren; Zhijin Fan; Xiaotian Ji; Bethany Mundy-Bosse; Shunzong Yuan; Tiffany Hughes; Jianying Zhang; Baljash Cheema; Andrew T Camardo; Yong Xia; Lai-Chu Wu; Li-Shu Wang; Xiaoming He; A Douglas Kinghorn; Xiaohui Li; Michael A Caligiuri; Jianhua Yu
Journal:  J Immunol       Date:  2014-08-13       Impact factor: 5.422

7.  Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.

Authors:  N C Fernandez; A Lozier; C Flament; P Ricciardi-Castagnoli; D Bellet; M Suter; M Perricaudet; T Tursz; E Maraskovsky; L Zitvogel
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

8.  MicroRNAs activate natural killer cells through Toll-like receptor signaling.

Authors:  Shun He; Jianhong Chu; Lai-Chu Wu; Hsiaoyin Mao; Yong Peng; Christopher A Alvarez-Breckenridge; Tiffany Hughes; Min Wei; Jianying Zhang; Shunzong Yuan; Sumeet Sandhu; Sumithira Vasu; Don M Benson; Craig C Hofmeister; Xiaoming He; Kalpana Ghoshal; Steven M Devine; Michael A Caligiuri; Jianhua Yu
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

9.  Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1.

Authors:  Nicholas D Huntington; Hamsa Puthalakath; Priscilla Gunn; Edwina Naik; Ewa M Michalak; Mark J Smyth; Hyacinth Tabarias; Mariapia A Degli-Esposti; Grant Dewson; Simon N Willis; Noboru Motoyama; David C S Huang; Stephen L Nutt; David M Tarlinton; Andreas Strasser
Journal:  Nat Immunol       Date:  2007-07-08       Impact factor: 25.606

Review 10.  Human natural killer cell receptors and co-receptors.

Authors:  R Biassoni; C Cantoni; D Pende; S Sivori; S Parolini; M Vitale; C Bottino; A Moretta
Journal:  Immunol Rev       Date:  2001-06       Impact factor: 12.988

View more
  10 in total

Review 1.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

2.  Chitooligosaccharides Improve the Efficacy of Checkpoint Inhibitors in a Mouse Model of Lung Cancer.

Authors:  Astrid Zedlitz Johansen; Marco Carretta; Marie-Louise Thorseth; Shawez Khan; Klaire Yixin Fjæstad; Christian Beltoft Brøchner; Hannes Linder; Christina Ankjærgaard; Marco Donia; Inna Chen; Dorte Lisbet Nielsen; Claus Preibisch Behrens; Daniel Hargbøl Madsen
Journal:  Pharmaceutics       Date:  2022-05-12       Impact factor: 6.525

Review 3.  Recent Advances in Chitosan and its Derivatives in Cancer Treatment.

Authors:  Jingxian Ding; Yonghong Guo
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

Review 4.  A Review on Chitosan's Uses as Biomaterial: Tissue Engineering, Drug Delivery Systems and Cancer Treatment.

Authors:  Rayssa de Sousa Victor; Adillys Marcelo da Cunha Santos; Bianca Viana de Sousa; Gelmires de Araújo Neves; Lisiane Navarro de Lima Santana; Romualdo Rodrigues Menezes
Journal:  Materials (Basel)       Date:  2020-11-06       Impact factor: 3.623

5.  miR-582 Suppresses the Proliferation of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells and Protects Them From Natural Killer Cell-Mediated Cytotoxicity.

Authors:  Xinxin Li; Yufei Zhang; Fei He; Dan Gao; Bo Che; Xiuli Cao; Siyong Huang; Minhua Zheng; Hua Han
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

6.  Chitosan-Based Delivery of Avian Reovirus Fusogenic Protein p10 Gene: In Vitro and In Vivo Studies towards a New Vaccine against Melanoma.

Authors:  Claudia Robles-Planells; Carlos Barrera-Avalos; Leonel E Rojo; Eugenio Spencer; Marcelo Cortez-San Martin; Silvia Matiacevich; Jorge Pavez; Luis A Milla; Franco D Navarro; Brandon A Martínez; Francisco J Bravo; Andrea Mella; Juan Pablo Huidobro-Toro; Ricardo Fernandez; Alejandro Escobar; Claudio Acuña Castillo
Journal:  Biomed Res Int       Date:  2020-06-13       Impact factor: 3.411

7.  Ultrasound-responsive highly biocompatible nanodroplets loaded with doxorubicin for tumor imaging and treatment in vivo.

Authors:  Xiaoying Zhou; Lu Guo; Dandan Shi; Dong Meng; Xiao Sun; Mengmeng Shang; Xinxin Liu; Yading Zhao; Jie Li
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 8.  Targeting the RNA m6A modification for cancer immunotherapy.

Authors:  Xinxin Li; Shoubao Ma; Youcai Deng; Ping Yi; Jianhua Yu
Journal:  Mol Cancer       Date:  2022-03-16       Impact factor: 27.401

9.  Chitosan-Based Nanoparticles for Intracellular Delivery of ISAV Fusion Protein cDNA into Melanoma Cells: A Path to Develop Oncolytic Anticancer Therapies.

Authors:  Claudia Robles-Planells; Giselle Sánchez-Guerrero; Carlos Barrera-Avalos; Silvia Matiacevich; Leonel E Rojo; Jorge Pavez; Edison Salas-Huenuleo; Marcelo J Kogan; Alejandro Escobar; Luis A Milla; Ricardo Fernandez; Mónica Imarai; Eugenio Spencer; Juan Pablo Huidobro-Toro; Claudio Acuña-Castillo
Journal:  Mediators Inflamm       Date:  2020-04-29       Impact factor: 4.711

Review 10.  Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis.

Authors:  Jorge Matías-Guiu; Jordi A Matías-Guiu; Paloma Montero-Escribano; Juan A Barcia; Alejandro A Canales-Aguirre; Juan C Mateos-Diaz; Ulises Gómez-Pinedo
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.